the vaccine

[키워드] 1:1 501Y.V2 95% CI 95% confidence interval acute respiratory syndrome African age Analysis analyzed assessment assigned AZD1222 B.1.351 B.1.351 variant caused ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine clinical conducted coronavirus Coronavirus 2019 D614G dose double-blind Efficacy end point enrolled foundation greater groups HIV HIV-negative Human immunodeficiency virus incidence laboratory-confirmed less median age Melinda Gate Mild-to-moderate multicenter Neutralization assay Pan participant Placebo placebo recipient placebo recipients Population primary end point primary end-point pseudovirus randomized, controlled trial receive recipient registry Result SARS-CoV-2 SARS-CoV-2 variant second dose Serious Adverse Event serum sample show protection against Sodium chloride South Africa symptomatic tested the vaccine two-dose regimen Vaccine variant viral particle virus
[DOI] 10.1056/NEJMoa2102214 PMC 바로가기 [Article Type] Clinical Trial